InterMune, Alnylam propose follow-ons

InterMune Inc. (NASDAQ:ITMN) and Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) proposed follow-ons late Monday. InterMune said it plans to raise a total of about $210 million through the sale of 12.5 million shares in a follow-on and $85 million in convertible senior notes due 2017. If the shares are sold at InterMune's close on Monday of $9.99, the company would raise $124.9 million in the follow-on. Goldman Sachs and JPMorgan are underwriting InterMune's offerings. InterMune, which markets Esbriet pirfenidone in the EU for idiopathic pulmonary fibrosis (IPF), was off $0.23 to $9.99 on Monday. ...